Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 6/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28362069 | 1.00 | CYP2C19 (0.41) | CYP2C19TSHRCYP2D6CYP3A4CASP1 | |
| SCHEMBL15577084 | 1.00 | CYP2C19 (0.41) | CYP2C19TSHRCYP2D6CYP3A4CASP1 | |
| SCHEMBL15616244 | 1.00 | CYP2C19 (0.41) | CYP2C19TSHRCYP2D6CYP3A4CASP1 | |
| SCHEMBL15616245 | 1.00 | CYP2C19 (0.41) | CYP2C19TSHRCYP2D6CYP3A4CASP1 | |
| SCHEMBL15616241 | 1.00 | CYP2C19 (0.41) | CYP2C19TSHRCYP2D6CYP3A4CASP1 | |
| SCHEMBL15577083 | 1.00 | CYP2C19 (0.41) | CYP2C19TSHRCYP2D6CYP3A4CASP1 | |
| SCHEMBL15616243 | 1.00 | CYP2C19 (0.41) | CYP2C19TSHRCYP2D6CYP3A4CASP1 | |
| SCHEMBL15616242 | 0.83 | CA1 (0.42) | CYP2C19TSHRCYP2D6CYP3A4CASP1 | |
| SCHEMBL15616207 | 0.83 | CA1 (0.42) | CYP2C19TSHRCYP2D6CYP3A4CASP1 | |
| SCHEMBL15616240 | 0.83 | CA1 (0.42) | CYP2C19TSHRCYP2D6CYP3A4CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2025-10-30 | — | — | US | disclosed |
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-11-07 | — | — | US | disclosed |
| US-11926619-B2 | Certain pladienolide compounds and methods of use | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2024-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368140-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | CYP2C19 3864/4885TSHR 4565/4885CYP2D6 3334/4885 |
| US-20250333400-A1 | CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE | SNRPE, SNRPB2, DDX21 | CYP2C19 4464/4885TSHR 4772/4885CYP2D6 3455/4885 |
| US-11926619-B2 | Certain pladienolide compounds and methods of use | PLAAT5, PLAAT3, PLAAT4 | CYP2C19 3864/4885TSHR 4565/4885CYP2D6 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.